AXNX Live signals | Maximize Profits with Getagraph.com

BUY 8249 min ago

@ $66.97

Issued: 28 May 2024 @ 09:31

Return: 0.18%

Previous signal: May 24 - 09:30

Previous signal: Sell

Return: -0.79 %

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

Stats
Today's Volume	345 569
Average Volume	684 409
Market Cap	3.42B
EPS	$0 ( 2024-05-06 )
Next earnings date	( $0.0800 ) 2024-07-25
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-216.42
ATR14	$0.0200 (0.03%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-31	Sama Rinda	Buy	28 000	Common Stock
2024-01-31	Sama Rinda	Sell	17 500	Performance-Based Restricted Stock Units
2024-01-31	Noblett Karen	Buy	27 500	Common Stock
2024-01-31	Noblett Karen	Sell	11 288	Common Stock
2024-01-31	Noblett Karen	Sell	15 000	Performance-Based Restricted Stock Units

INSIDER POWER
-2.11
Last 98 transactions
Buy: 597 788 \| Sell: 539 127

Volume Correlation

Long: 0.25 (neutral)

Short: -0.54 (weak negative)

Signal:(57.598) Neutral

Axonics Modulation Correlation

10 Most Positive Correlations
OZEM	1
JDZG	0.965
XOMAP	0.847
BTOC	0.827
BWIN	0.823

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Axonics Modulation Correlation - Currency/Commodity

0.43
( neutral )

0.00
( neutral )

0.48
( neutral )

-0.58
( weak negative )

Axonics Modulation Financials

Annual	2023
Revenue:	$366.38M
Gross Profit:	$265.49M (72.46 %)
EPS:	$-0.120

FY	2023
Revenue:	$366.38M
Gross Profit:	$265.49M (72.46 %)
EPS:	$-0.120

FY	2022
Revenue:	$273.70M
Gross Profit:	$197.67M (72.22 %)
EPS:	$-1.280

FY	2021
Revenue:	$180.29M
Gross Profit:	$115.72M (64.18 %)
EPS:	$-2.17

Financial Reports:

No articles found.

Axonics Modulation Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Axonics Modulation

Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct salesforce and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.